All Clyde Biosciences services are based on human-relevant models, replacing traditional animal models with predictive cardiomyocyte systems and in vitro cardiomyocytes assays. This approach improves translational accuracy and aligns with evolving FDA guidelines and global regulatory guidance.
CiPA Cardiac Safety Assessment
Accurately predict proarrhythmic risk, generating data suitable for IND submissions and aligned with regulatory-led CiPA initiatives with a cardiomyocyte safety assay.
Mechanistic Cardio Toxicity Analysis
Define cardiovascular risk with greater precision with our in vitro cardiomyocyte assay. Measure electrophysiology, calcium dynamics, and contractility during acute and prolonged compound exposure.
Heart Failure and Efficacy Assay
Evaluate therapeutic candidates for heart failure using hiPSC cardiomyocytes and adult cardiomyocytes, generating functional data on electrophysiology, calcium handling, and contractility to support efficacy and safety decisions.
hiPSC Cardiomyocyte Characterisation
& Validation
Benchmark and validate hiPSC-derived cardiomyocytes to ensure consistency, reliability, and suitability for cardiac safety and efficacy studies.
Voltage / Action Potential Analysis
Capture high-resolution action potential data, including upstroke dynamics, with sensitivity beyond traditional assays to detect subtle electrophysiological changes.
Calcium Dynamics Analysis
Measure calcium transients at high throughput in human cardiomyocytes to assess excitation–contraction coupling and identify compound-induced dysfunction.
Contractility and Functional Assessment
Quantify cardiomyocyte contraction with high frequency visual measurements to detect drug induced changes in cardiac performance and identify negative inotropic effects.
In Silico Cardiac Modelling
Integrate experimental data with computational models to improve prediction of human cardiac risk and support regulatory decision-making.
Custom Cardiac Safety and Efficacy Studies
Tailored study design to address specific cardiac liabilities, from early discovery through IND-enabling programs.